Could Johnson & Johnson's conditions on 340B drug sales to hospitals involving contract pharmacy be the thunderclap that rouses Congress?
Could J&J’s Decision to Limit 340B Contract Pharmacy Spur Congress to Act?
Yesterday, we broke the news that Johnson & Johnson announced conditions on 340B drug sales to hospitals on a host of pharmacy inventory staples including immunosuppressants, monoclonal antibodies, blood thinners, and treatments for diabetes, cancer, HIV, mental disorders, pulmonary arterial hypertension, and chemotherapy-induced anemia. Federal grantee covered entities are exempt.
J&J is the world’s biggest drug company. Its decision to restrict 340B pricing is significant financially and symbolically. With the federal court fight over 340B contract pharmacy years away from resolution, and the U.S. Health and Human Services Department (HHS) having taken no 340B enforcement action against drug companies since September, J&J’s policy could be a thunderclap that rouses Congress.
J&J is the world’s biggest drug company. Its decision to restrict 340B pricing when hospitals use contract pharmacies could be a thunderclap that rouses Congress.